Pt. A: Ph I, Sngl-Blind, Randomized, Pcbo-Controlled 3-Way Crossover Study Followed by an Open-label Food Effect Study to Assess the PK of IV and Oral AZD6765 in Healthy Male and Female Subjects Pt.B: Ph I, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and PK of AZD6765 When Administered in Multiple Ascending Doses to Healthy Subjects.

Trial Profile

Pt. A: Ph I, Sngl-Blind, Randomized, Pcbo-Controlled 3-Way Crossover Study Followed by an Open-label Food Effect Study to Assess the PK of IV and Oral AZD6765 in Healthy Male and Female Subjects Pt.B: Ph I, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and PK of AZD6765 When Administered in Multiple Ascending Doses to Healthy Subjects.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Lanicemine (Primary) ; Lanicemine (Primary)
  • Indications Depressive disorders
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Oct 2014 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 20 Jan 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 31 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top